Nested Therapeutics

Listen in as Meagan Ryan, Senior Scientist, Biology, sheds light on the RAS- and RAF-driven cancers. They are notoriously difficult to treat clinically and, outside of BRAF Class I- and KRAS G12C-mutant cancers, have no approved targeted therapies. NST-628 is a pan-RAF-MEK non-degrader molecular glue that is positioned to make a broad impact in areas of unmet patient needs. You can read more about it here: https://lnkd.in/gBz-dmpH

Very proud of Darrin Miles for sharing our incredible progress at #AACR24! This is all possible thanks to our exceptionally dedicated team!  

Our CSO, Klaus Hoeflich, recently sat down with Sally Church for an insightful interview on Nested’s progress. Delve into how we’re translating scientific insights, what sets us apart and discover our impressive journey from concept to clinic in just three years. Check out the interview on Biotech Strategy Blog to learn more. #NST628 #NestedTherapeutics #Biotech

Today, at the American Association of Cancer Research Annual Meeting, Nested’s lead program, NST-628, was featured in an oral presentation as part of the “New Drugs on the Horizon” series, and our CSO, Klaus Hoeflich, shared pre-clinical data on our non-degrading molecular glue and its potential to inhibit RAS- and RAF-driven cancers. https://lnkd.in/gKf_fEQt Further details on NST-628 can be found in the article “The pan-RAF-MEK non degrading molecular glue NST-628 is a potent and brain penetrant inhibitor of the RAS-MAPK pathway with activity across diverse RAS- and RAF-driven cancers“ published concurrently in Cancer Discovery. The Phase 1 study of NST-628 is now open and enrolling patients with advanced solid tumors. We are proud of our team to have achieved this significant milestone in our mission to provide cancer patients with better treatment alternatives.    For more insights, visit our website and stay tuned for more updates! #NST628 #AACR24

Kicking off #AACR24 with a stride of solidarity! Our very own, Meagan Ryan, hit the pavement in the 5K Runners for Research, expanding our support from coast to coast. Way to crush it, Meagan!

New Drugs on the Horizon: The AACR Chemistry in Cancer Research Working Group is hosting this three-part series of sessions during #AACR24 (April 7-8). The sessions will present 12 first-time disclosures of novel agents against emerging cancer targets. Learn more: https://bit.ly/3PKR01u

Exciting news from Nested Therapeutics! Today, we're proud to announce the FDA clearance of our Investigational New Drug (IND) Application for NST-628, Nested’s mechanistically novel, non-degrading Pan-RAF/MEK molecular glue for the treatment of RAS and RAF-driven tumors. Additionally, our CSO, Klaus Hoeflich, will present pre-clinical data on NST-628 at the “New Drugs on the Horizon” Series at the 2024 AACR Annual Meeting. Stay tuned for more updates as we continue our commitment to address hard-to-treat cancers. #NestedTherapeutics #AACR24 #NST628 To read more, visit nestedtx.com

Can you believe we hit our 3-year mark as a company!! The team got together during our monthly happy hour for some Nested trivia because what's a celebration without a little friendly competition, right? 🏆 It's incredible to see how far we've come and the incredible team we've built along the way. Here's to many more years of growth, innovation, and memories together! #NestedTurns3

Happy International Pi Day!! It's a sweet day at Nested thanks to some very talented bakers on our team!

Today, we announce the appointment of three members to our board of directors. “Anna, John and Tom each brings a diversified skillset spanning biopharma entrepreneurship, operational and commercial expertise, and deep oncology drug development experience. We look forward to partnering with them as we continue to build our pipeline and advance our first program into the clinic this year.” - Darrin Miles, CEO, Nested Therapeutics Learn more about us at https://nestedtx.com/